scholarly article | Q13442814 |
P356 | DOI | 10.1111/1744-9987.12430 |
P698 | PubMed publication ID | 27312908 |
P50 | author | Jakob Gubenšek | Q43289012 |
P2093 | author name string | Jelka Lindic | |
Damjan Kovac | |||
Rafael Ponikvar | |||
Aljosa Kandus | |||
Jadranka Buturovic-Ponikvar | |||
Miha Arnol | |||
Karmen Romozi | |||
Andreja Ales Rigler | |||
P2860 | cites work | Adverse events in apheresis: An update of the WAA registry data | Q26771588 |
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial | Q33584895 | ||
Revisiting traditional risk factors for rejection and graft loss after kidney transplantation | Q35250310 | ||
Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection | Q36752176 | ||
Banff 2011 Meeting report: new concepts in antibody-mediated rejection | Q37058043 | ||
The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. | Q38049098 | ||
Antibody-mediated vascular rejection of kidney allografts: a population-based study | Q38062614 | ||
Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. | Q38169496 | ||
New insights in antibody-mediated rejection | Q38248369 | ||
Intravenous immunoglobulin in kidney transplantation | Q38625172 | ||
Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure | Q43918875 | ||
Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience | Q44103494 | ||
A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection | Q44197767 | ||
Impact of rituximab therapy for treatment of acute humoral rejection | Q45361905 | ||
Early versus late acute antibody-mediated rejection in renal transplant recipients. | Q46415040 | ||
Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation | Q46873864 | ||
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation | Q56907959 | ||
P433 | issue | 3 | |
P304 | page(s) | 240-245 | |
P577 | publication date | 2016-06-01 | |
P1433 | published in | Therapeutic Apheresis and Dialysis | Q15759076 |
P1476 | title | Treatment of Antibody-Mediated Rejection After Kidney Transplantation - 10 Years' Experience With Apheresis at a Single Center | |
P478 | volume | 20 |
Q64114462 | C5b9 Deposition in Glomerular Capillaries Is Associated With Poor Kidney Allograft Survival in Antibody-Mediated Rejection |
Q47286616 | Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. |
Q89782890 | The Preliminary Results of Bortezomib Used as A Primary Treatment for An Early Acute Antibody-Mediated Rejection after Kidney Transplantation-A Single-Center Case Series |
Q58754949 | Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results |
Search more.